G280 Stock Chart & Stats
€7.70
€0.00(0.00%)
At close: 4:00 PM EDT
€7.70
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.90 - €46.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€16.60M
Enterprise Value€33.34
Total Cash (Recent Filing)€692.30K
Total Debt (Recent Filing)€3.07M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.84
Shares Outstanding4,219,343
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary T‑cell PlatformA focused, proprietary T‑cell platform represents a durable strategic asset: platform technologies can be applied across viral infections and oncology to generate multiple candidates, attract partnerships, and create long‑term value if clinical progress validates mechanisms.
Reduced Debt BurdenMaterial reduction in debt versus prior years improves near‑term financial flexibility and lowers mandatory interest and covenant pressure, permitting management to prioritize R&D investment and partnership or licensing opportunities without as large a fixed‑cost drag.
Improving Loss TrendAn improvement in operating losses versus 2023 suggests management is executing cost discipline or program prioritization; sustained improvement can extend runway, reduce frequency of dilutive raises and support clearer milestones for partnering or non‑dilutive financing.
Bears Say
No Revenue / Persistent LossesThe absence of revenue means the business remains entirely pre‑commercial and dependent on R&D success; persistent operating and net losses increase execution risk, amplify the need for external funding, and make long‑term viability contingent on clinical outcomes or deals.
Sustained Cash BurnOngoing negative operating and free cash flow at material TTM levels creates continuous funding needs; this structural cash burn pressures runway, raises likelihood of dilutive equity raises, and constrains the ability to scale programs or respond to setbacks without new capital.
Negative Shareholders' EquityA persistently negative equity base signals a fragile capital structure that can impede borrowing, heighten insolvency risk in stress scenarios, and increase dependence on equity financing, which can dilute existing holders and complicate long‑term strategic planning.
Tevogen Bio Holdings News
G280 FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was €6.90 and its highest was €46.50 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is €16.60M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Aug 13, 2026 which is in 17 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Jun 03, 2026. The company reported -€1.412 earnings per share for the quarter, beating the consensus estimate of -€2.313 by €0.901.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 4,219,343 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -€1.412 in its last earnings report, beating expectations of -€2.313. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in DE:G280
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―